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Background: A plethora of clinical studies have assessed the benefits of implantable cardioverter defibrillators
(ICDs) and supported their use in clinical practice. However, evidence on the safety and efficacy of ICDs appears
insufficient to support expansion of their use in clinical practice, and more information on their impact in real life
settings is warranted. This paper aims to investigate the impact of ICDs using a large administrative dataset
reflecting actual clinical practice.
Methods: Data were obtained from the hospital discharge database of the Friuli Venezia Giulia region in Italy
containing patient-level information on 169,488 cases. Data on mortality outside hospital were obtained from
regional sources. Exact matching method was used to estimate the outcomes associated with ICDs: mortality,
length of stay, re-hospitalization and regional expenditure. The method was applied in two steps. First, patients
with ICDs were matched with those without using the following: age class (by 5 years), gender, year of admission,
type of admission (day hospital vs. ordinary) and primary diagnosis. In the second step, matching included also
Charlson Comorbidities Index. Exact matching average treatment effect on the treated (ATT) was used as a main
measure of impact.
Results: Compared with matched controls, treatment with ICDs was associated with lower mortality (absolute risk
reduction 10.6% at 1 year and 8.3% at 2 and 8.4% at 3 years, p < 0.001 and hazard ratio 0.80, p < 0.001), greater
regional expenditure at index hospitalization (ATT: €9459.64, p < 0.001) and during follow up (ATT: €1707.29, p <
0.001) and higher re-hospitalization rate (ATT: 0.53, p < 0.001). No significant difference was found for length of stay
(9.07 vs. 8.86 days). The results were maintained after more restrictive matching was applied.
Conclusions: Assessing the impact of innovative, expensive medical technologies on the basis of real world data is
warranted, especially when there are barriers to implementation. Hospital administrative datasets can be of great
value when a technology such as the ICD is implemented in a relatively small sample of patients, to allow use of
exact matching techniques.
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Despite improvements in prevention and treatment strat-
egies, cardiovascular diseases continue to represent a lead-
ing public health problem worldwide [1-4]. A plethora of
studies have assessed the benefits of new technologies used
in cardiology and support their use in clinical practice.
However, accumulated evidence on the safety and efficacy
of an innovation is not sufficient to support its widespread
application. Owing to limited availability of the resources
required for the use of new innovations, medical decisions
are increasingly influenced by economic considerations.
This is particularly evident in cardiology, where innovations
are associated with significantly higher upfront costs that
often create barriers to their use [5].
The implantable cardioverter defibrillator (ICD), intro-
duced for the prevention of sudden cardiac death, is one of
the most challenging examples in this regard. The deploy-
ment of ICDs in standard clinical practice has brought
marked clinical benefits to the population at risk of fatal ar-
rhythmias and dramatically changed the management of
patients at risk of sudden cardiac death. The impact of
ICDs on survival has been thoroughly investigated in nu-
merous randomized clinical studies and the role of ICDs in
preventing sudden cardiac death has been established for
both secondary prevention (in patients who have already
suffered a major cardiac event such as ventricular arrest)
and primary prevention (in patients who are at risk of sud-
den cardiac death but have not yet suffered cardiac arrest).
The weight of evidence supporting the clinical efficacy of
ICDs in selected patients led to their inclusion in consensus
guidelines issued by professional societies in both Europe
and the United States [6]. A recent review suggests that
ICDs are efficacious in reducing all-cause mortality in the
adult population, with an effect ranging from 20% (95%
confidence interval (CI) 10–29%) in randomized clinical tri-
als to 46% (95% CI 32–57%) in observational studies [7].
However, evidence suggests that clinical guidelines are
not always fully adopted owing to the presence of barriers
to the widespread use of ICDs [8,9]. Their high upfront cost
has been discussed as the major limiting factor: 88% of cli-
nicians report financial barriers as the major obstacle, while
lack of expertise and lack of national guidelines are per-
ceived as potential barriers by 61% and 51% of clinicians,
respectively [9]. Other factors that have been mentioned in-
clude organizational, administrative and cultural issues [10].
The literature on ICDs highlights two issues requiring
further exploration. The first concerns the use of “real
world” (i.e. observational) data for the evaluation of
medical technology. This issue is particularly relevant
for ICDs, because the reality can differ significantly from
what is suggested by consensus guidelines. Validation of
the potential benefits initially observed in clinical studies
with data collected in real world medical practice is thus
of crucial importance. Differences between the resultsobtained in these two settings can be of great value for
healthcare providers, policy makers and producers of in-
novative technologies [11]. The second issue is related to
the time over which analyses are conducted. Because
ICDs are preventive devices, the importance of taking a
long-term perspective when evaluating their impact is
obvious. According to a recent review, however, no clin-
ical trial has followed-up patients beyond 5 years. In par-
ticular, among published randomized controlled trials
(RCTs), time limits of 4.5 years in secondary prevention
and 3.5 years in primary prevention have been used [7].
These two issues (the need for real world data and a
long-term perspective) have led to the establishment of sev-
eral national and international registries to monitor and val-
idate ICD use in routine clinical practice [12]. Data
collected in these registries have given rise to numerous
publications showing that adoption rates differ significantly
across countries, even within the European Union. More
specifically, according to national registries, it has been
reported that, in 2008, the number of implants per million
inhabitants was 70–90 in Sweden, the United Kingdom and
Spain, 100–130 in France, Norway and Slovakia, 130–160
in Austria, Belgium and Switzerland, 160–200 in The
Netherlands and Czech Republic, 228 in Denmark, 262 in
Germany and 309 in Italy [13]. These differences suggest
that attitudes toward the implementation of ICD therapy,
especially in the context of primary prevention [8], are not
homogeneous, again raising doubts about the gene-
ralizability of results from clinical trials and adherence to
international guidelines.
Although studies based on registry data provide valuable
insights into major differences in implant rates across coun-
tries, they are rarely used to evaluate the impact of ICDs
[10,12-14]. The main problem here is that these studies do
not generally identify any “control group”, with the obvious
consequence that it is usually not possible to assess the
short- and long-term effectiveness of the ICDs. An alterna-
tive approach is needed to better exploit information
obtained from observational datasets.
The purpose of this paper is to fill this gap in the em-
pirical literature. More specifically, the present study
contributes to the existing literature in two ways. First,
from a policy point of view, it provides a first quantita-
tive assessment of the impact of an innovative technol-
ogy (the ICD) in a real life setting. As mentioned above,
this type of evidence is of paramount importance for de-
cision making when allocating scarce healthcare re-
sources. Second, from a methodological point of view,
our paper approaches the impact evaluation exercise by
directly using information from hospital records, origin-
ally collected for administrative purposes, from a region
of Italy. The data used here are routinely stored by
health authorities in many other European countries.
Hence, the methodology proposed can be extended to
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in different policy contexts and health systems.
The paper is organized as follows. In the next section, we
describe the databases used, followed by essential descrip-
tive statistics to set the context for the data analysis. In the
subsequent section, we present the results, while the dis-
cussion is dedicated to interpretation and study limitations.
We draw some conclusions in the final section.
Methods
Data source
The data were obtained from the hospital discharge data-
base of the Friuli Venezia Giulia (FVG) region of Italy
(Scheda Dimissione Ospedaliera, Major Diagnostic Cat-
egory 5 – Disease and Disorders of the Circulatory Sys-
tem). These type of data are routinely collected by all the
hospitals in the region and include information on pa-
tients socio demographic characteristics and treatment
received during hospitalization.
FVG is in the northeastern part of Italy and has ap-
proximately 1.2 million inhabitants. As in the rest of
Italy, all citizens are covered by taxed-based public health
insurance. Since 1995, hospital care services delivered by
public or private accredited hospitals in Italy are reim-
bursed on “per case” basis, classified according to Diag-
nosis Related Groups (DRGs). Each group is assigned a
specific “value” (tariff ) reflecting the intensity of resource
consumption needed to treat patients assigned to that
group. Costing for the purpose of tariff setting is mainly
performed at regional level. Given that cost assessment
represents essential part for defining value of DRG tariff,
the latter is frequently used as the “proxy” of hospital
costs of specific patient group.
We observed all patient records for the period 1997–
2007 from all service providers in the region (24 hospi-
tals). A total of 334,764 observations (admissions) and
169,488 patients were included in the analysis. For each
observation, data included information on hospital diag-
nosis and procedures (International Classification of Dis-
eases, 9th revision (ICD9), Clinical Modification codes),
inpatient mortality, hospitalization and discharge dates,
DRG tariffs and demographic variables (municipality of
patient residence, age and sex). In addition, we merged
this database with another regional administrative data
set recording outpatient mortality from 1997 to 2009.
This was particularly important in our context because,
given the preventive nature of ICD treatment, inpatient
mortality alone would have been a poor indicator of
effectiveness.
As in other retrospective studies designed to assess
current clinical practice [10], the current regulations of
ethics committees in Italy require only standard written
informed consent at the time of device implanta-
tion (obtained from all patients in line with nationalregulations) and anonymous publication of scientific
data. Our retrospective observational study, conceived
and performed in accordance with the principles of the
most recent revision of the Declaration of Helsinki, ful-
filled these requirements.
The average age at admission of all patients hospital-
ized in cardiology departments in FVG during the 11 -
years was approximately 70 years. Females represented
48.77% of the sample. On average, each patient stayed in
hospital for approximately 9 days and was re-hospitalized
1.4 times. Overall in-hospital mortality was 5.5%. The
total hospital expenditure per patient was €13,358 during
the observation period, and the average DRG tariff for a
single admission was €3395. Crucially, over the 10-year
observation period, only 1213 ICDs were implanted
(0.36% of the observed hospitalizations). Methodologic-
ally, this characteristic of the data is important, because
it shows that ICD treatment is numerically a rare event
and should be analyzed with the proper statistical tools.
It is interesting to note, however, that the number of
hospitalizations for ICD treatment increased steadi-
ly throughout the observation period, though it re-
mained relatively low reaching maximum 0.80% in 2007
(Figure 1).
Data analysis
To evaluate the impact of ICDs, we identified the follow-
ing outcome variables: mortality, length of stay (LOS),
re-hospitalization rate and regional expenditure. Mortal-
ity obviously represents an important final end point
that directly reflects the effectiveness of ICD treatment.
The other three quantities might be considered proxies
of resource consumption associated with ICD use. From
empirical evidence in the literature, we should expect
mortality to be reduced when ICDs are implanted. Sim-
ultaneously, we should expect expenditure to be in-
creased for ICD patients. We did not have any particular
a priori expectations regarding how long patients treated
with an ICD might stay in hospital (LOS) or how many
times they might have to be re-hospitalized.
ICD implantation is a rare event. Evidently, direct com-
parison between ICD patients and the rest of the sample
would not be informative because the ICD patients
would be compared with a very large and heterogeneous
control group comprising patients hospitalized for a wide
variety of different pathologies and health problems. This
could significantly bias the results. For example, treat-
ment with an ICD could be associated with higher than
average mortality simply because ICDs are used in people
at high risk of future heart failure.
The general approach taken in this paper was to use
exact matching methodology to select a subsample of
homogeneous records. The variables used for matching
















Figure 1 Diffusion of ICDs in Friuli Venezia Region 1997-2007 (% of patients with ICDs over total number of hospitalizations in MDC 5).
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pital vs. ordinary), primary diagnosis and comorbidities.
Exact matching is a relatively straightforward technique
and is particularly suited to situations in which the treat-
ment is a rare event [15,16].
In our case, for each patient who received an ICD (treat-
ment group), we selected a group of patients with the
exactly same characteristics (control group) and compared
their outcomes with simple mean difference analyses. More
specifically, in our analysis we evaluated what is known as
the average treatment effect on the treated (ATT), which,
in this case, measures the impact of the ICD on the people
that received one. The method adopts the following ap-
proach: once the subsample of patients with the same char-
acteristics had been selected, the impact of the ICD on a
certain outcome was measured by comparing the outcome
for each single ICD patient (case) with the average outcome
of all of the matched patients without the ICD (control). As
specified above, matching was done on exact values. This
means that each single case was compared with a control
with exactly the same characteristics (in terms of covari-
ates), but with an “artificial” outcome obtained by averaging
all of the possible matched controls. In this method stand-
ard errors and the t-test are not straightforward to apply
and need adjustments. For this reason, we used the
nnmatch STATA command, which calculates the correct
variance and CIs [17].
The most important variables for matching are the pri-
mary diagnosis and comorbidities, which in our dataset was
codified according to the ICD9-CM. Each hospital admis-
sion was associated with up to six of these codes. Because
there are many possible combinations of six variables, we
followed a two-step matching procedure. First, patients
were selected according to their primary diagnosis; that is,
we selected a control group of patients who had exactly the
same primary diagnoses as the corresponding ICD patients
(subsample 1). In the second step, we accounted for comor-
bidity by calculating the Charlson comorbidity index (CCI)
for the ICD9 classification. This index provides a numericalstratification of the severity of the comorbidities associated
with the diagnostic codes. In our case, the CCI was applied
to the diagnoses not used in the first step (diagnosis two to
six). Once the CCI index for each observation was ob-
tained, further matching was applied (subsample 2).
Since we observed hospitalizations to the end of 2007
and outpatient mortality to the end of 2009, follow-up
ranged from a minimum of 2 years to a maximum of 10 -
years. However, since the year of hospitalization is in-
cluded in the matching process the follow-up period, by
definition, could not differ significantly between the
treatment and the control group. In our analysis we ob-
serve mortality at different points in time following
hospitalization (at 1, 2 and 3 years).
It is important to distinguish between the subsample
used for analysis and the sample used matching. Because
matching builds a 1:1 counterfactual, the case and con-
trol groups are by definition numerically equal and per-
fectly balanced in their covariates. However, the selected
subsample does not need to have these characteristics
since the number of controls for each case may vary.
Regarding the assessment of mortality, since the day of
death cannot be “averaged” in the control group, exact
matching cannot provide an analysis of the hazard ratios
related to ICD use. Consequently, it is reasonable to as-
sess the robustness of our results from exact matching
by applying a regression-based parametric approach to
the selected subsamples. We applied a Weibull regres-
sion analysis on the selected subsamples, using the diag-
nostic variables as controls.
Finally, it should be noted that ICDs were available
from only eight of the 24 hospitals in FVG. One might
have been tempted to use hospital as a further matching
variable. However, if an ICD is not implanted in a center
where this treatment is available, it is likely that the deci-
sion depended on factors known to the doctors but un-
observed by the analyst (see the last section for a
discussion of this issue). Hence, one possible selection
strategy is to pick the control group only from those
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risk of no-ICD being dependent on unobserved factors,
and is the approach we took in the following analysis,
though it should be noted that the results change little if
hospital is used as a matching variable.
Results
Table 1 reports main descriptive statistics on the two sub-
samples before and after matching. Subsamples 1 and 2
were obtained by considering different specifications of the
diagnosis variable, as described in the previous section.
When only the primary diagnosis is considered (subsample
1), 1050 patients, from a total of 13,029, received an ICD.
Matching for CCI halved the size of the control group
(5962 vs. 11976), whereas the treatment group was reduced
to 905 units.
Considering after-matching sample characteristics, aver-
age age changed little, whereas the proportion of male pa-
tients was approximately 80%. This is because, in the
original dataset, only approximately 16% of the patients
who were given an ICD were female. Thus, proportions
were maintained in the matched sample also with regard to
gender. The most common primary diagnosis among pa-
tients with ICDs was primary cardiomyopathy (41%),
followed by paroxysmal ventricular tachycardia (23%). A
secondary diagnosis was registered in 60% of the ICD pa-
tients, with congestive heart failure in 30% of cases.
Table 1 also shows after-matching standardized differ-








Age 65.90 (12.02) 70.40 (10.09)
Gender (Female) 0.15 (0.35) 0.16 (90.38)
Charlston Index = 0
Charlston Index = 1
Charlston Index = 2
Outcomes
LOS 9.15 (11.9) 9.05 (9.72)
Re-hospitalization rate 2.11 (3.51) 1.54 (2.52)
Mortality 0.29 (0.45) 0.47 (0.50)













Legend: Sub-sample 1: ICD and non ICD patients with the same primary diagnosis
primary diagnosis and Charlson index (+ other controls; Case: Patients with ICD; Co
standardized differences between case and control groups; LOS = Length of Stay inbecause we used exact matching, a balance among the co-
variates was by definition always achieved. It was not null
in the “age” covariate because we used 5-year age classes in-
stead of actual age for matching. However, there was clearly
no balancing problem. The after-matching standardized dif-
ferences for the outcomes (LOS, re-hospitalization rate,
mortality and expenditure) in Table 1 give an initial idea of
the size and the sign of the impact that we measure more
precisely below.
Results for series of outcomes are reported in Table 2.
Mortality at 1, 2 and 3 years was significantly lower in
patients with ICDs. Clearly, the impact of ICDs was ac-
centuated in the first year after implantation; the benefit
from ICD treatment in terms of mortality avoided
remained rather stable between the second and third
years. Note that the average treatment effect on mortal-
ity is a measure of the absolute risk reduction with an
ICD. Given that the mortality in the matched control
group was approximately 18% at 1 year, 27% at 2 years
and 45% at 3 years, the data in Table 1 imply relative risk
reductions of 0.59, 0.30 and 0.16, respectively. We also
determined the impact of ICDs on the number of life
years gained (LYG). This is calculated as minus the
case–control difference in the life years lost due to
death, that is, the difference between the age-sex specific
life expectancy in Italy in 2007 and age at death. This
measure assumes that patients surviving the observation
period will, on average, live as long as the rest of the
population. Our results show that an ICD is associatedSub-sample 2









−0.01 66.30 (10.58) 70.12 (9.83) −0.01
0 0.14 (0.35) 0.15 (0.35) 0
0.53 (0.49) 0.54 (0.50) 0
0.24 (0.43) 0.30 (0.46) 0
0.14 (0.35) 0.21 (0.41) 0
0.152 8.86 (11.24) 9.07 (9.40) 0.154
0.202 2.14(3.60) 1.57(2.42) 0.227












(+ other controls); Sub-sample 2: ICD and non ICD patients with the same
ntrols: Patients without ICD; Standardized difference = After-matching
day.






Mortality 1 year −0.106 −0.131 −0.082
Mortality 2 years −0.083 −0.114 −0.053
Mortality 3 years −0.084 −0.120 −0.049
Life years gained 1.190 0.657 1.723
LOS 0.112 −0.853 1.078
Re-hospitalization 0.533 0.325 0.742
Expenditure for index hospitalization (€) 9459.64 8793.73 10,125.54
Total hospital expenditure during follow up (€) 1707.29 539.25 2875.33
Matching 2
Mortality 1 year −0.088 −0.114 −0.062
Mortality 2 years −0.065 −0.097 −0.032
Mortality 3 years −0.060 −0.099 −0.021
Life years gained 0.762 0.202 1.323
LOS 0.089 −0.648 1.112
Re-hospitalization 0.591 0.360 0.818
Expenditure for index hospitalization (€) 9103.54 8543.86 9981.10
Total hospital expenditure during follow up (€) 1747.94 379.70 2997.16
Legend: Matching 1: exact matching on subsample 1; Matching 2: exact matching on subsample 2; Average treatment effect: average treatment effect on
patients with ICDs (mean difference between treatment and matched controls, adjusted for number of matches); Mortality 3 years: patients hospitalized in
2007 excluded.
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0.762 years in matching 1 to 1.190 in matching 2).
No significant difference between treatment and control
groups was found for LOS. However, re-hospitalization
rates were higher for ICD patients in both matching exer-
cises (Table 2).
Similar results were obtained for regional expenditure.
In our analysis, regional expenditure is reflected in the
value of DRG tariff paid to the hospital for each patient
included in the subsample. Differences in expenditure
between the treatment and control groups at index
hospitalization were almost constant at €10,000, which
reflects the difference in DRG tariff when the ICD is ini-
tially implanted. However, this difference drops signifi-
cantly during the follow up. In both matching steps, the
expenditure during the follow up for ICD patient is ap-
proximately €1700 higher than the control group, with
no significant differences between different matching ap-
proaches. This pattern reflects higher re-hospitalizations
in patients with ICD implanted, as mentioned above.
The same subsamples can be used to perform a robust-
ness check for the non-parametric matching described
above. Table 3 depicts a Weibull hazard model of the two
subsamples. Remember that, though the subsamples
were selected to have the same characteristics as the pa-
tients who received ICDs, the distribution of thesecharacteristics might vary between the treatment and
control groups. Hence, it is fundamental to control for
the same variables when performing a parametric ana-
lysis. This is why we continued to use the CCI and pri-
mary diagnosis as covariates. Also note that the Weibull
p is always significant and smaller than 1, indicating that
the risk of death declines over time. Results show a haz-
ard rate of 0.80 and 0.85 in subsample 1 and 2,
respectively.
Discussion
It was argued that real word data are more informative
and useful for decision makers than results from con-
trolled trial settings when evaluating medical technolo-
gies. This is particularly relevant in situations in which
clinical practice may significantly differ from clinical
guidelines owing to the presence of barriers to the full
implementation of technologies in clinical practice [14].
This effect has been observed in the introduction of
ICDs for the prevention of sudden cardiac death. To our
knowledge, this is the first empirical study that has
attempted to determine the impact of ICDs using an ad-
ministrative data set from a real world setting in Europe.
Administrative databases are recognized as valid sources
of data for identifying the outcomes of rare events
and for assessing the economic impact of various
Table 3 Hazard ratio for subsamples (Weibull hazard model)
Subsample 1 Subsample 2
Hazard 95% CI Hazard 95% CI
ICD 0.807 0.710 0.916 0.848 0.747 0.985
Age 1.053 1.049 1.057 1.057 1.049 1.051
Sex 0.705 0.651 0.764 0.681 0.651 0.601
Charlson comorbidity index 1.416 1.369 1.465 1.341 1.279 1.406
Weibull p 0.81 0.791 0.830 0.807 0.780 0.835
Likelihood Ratio (LR) (p-value) 3436.31 (< 0.0000) 1604.94 (< 0.0000)
All models included 48 dummies for primary diagnosis (coefficients not shown here); ICD: whether patient received an ICD (1) or not (0).
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tributes to the existing literature in two ways. First, it
provides additional evidence regarding the impact of
ICDs and estimates the magnitude of this impact across
four different dimensions. Second, and even more im-
portantly, it represents a novel study design in which an
exact matching method was used.
In this study, ICD treatment was associated with signifi-
cantly lower mortality, slightly higher re-hospitalization rate
and significantly higher regional expenditure. In our sam-
ple, mortality at 1 year was reduced by between 9% and
10%, with a relative risk reduction of 0.59. The hazard ratios
for the two subsamples were 0.80 and 0.85, respectively.
These findings are in line with those reported from RCTs
and collected in recent reviews, though direct comparisons
should be made with caution, considering the different
study designs [18]. A more significant difference is observed
in comparison with the results obtained from a meta-
analysis of other observational studies in which ICDs re-
duced all-cause mortality by 46% (CI, 32% to 57%) [7]. This
greater difference can be partially explained by the high het-
erogeneity of the studies selected for this review. Indeed,
among 11 observational studies with a contemporaneous
control group, only two can be compared with our present
study in terms of sample size and the method used to de-
termine the benefits of ICDs [19,20]. In line with our find-
ings, the relative risk reduction in all-cause mortality in
these two studies was 0.67 (CI 0.63–072 ) and 0.71 (CI
0.51–0.97), respectively.
Regarding re-hospitalization rate, the difference be-
tween the two groups was positive across all samples.
This result could have been expected, because ICD pa-
tients are more likely to return hospital for monitoring
of their device, though such visits do not necessarily be-
come hospitalization events.
The study of Groeneveld et al. [19] analyzed Medicare
patients given an ICD prophylactically and found in-
creases in both survival and expenditure compared with
propensity score-matched elderly patients who did not
receive an ICD. This analysis differs from ours in terms
of the method, the patients’ age (mean 76 years) and the
context. The purchase price of an ICD is higher in theUnited States than in Europe, and specifically in Italy
[20,21], and therefore American data cannot be directly
related to the setting of our health care system. However,
it is noteworthy that these two studies led to similar
conclusions with regard to ICD costs and benefits. More
recently, another report derived from Medicare data
showed how geographical areas in which the prophylac-
tic use of ICDs increased over time showed greater
improvements in survival, stressing the need for pro-
grams designed to increase the evidence-based use of
ICDs [22].
In our study, regional expenditure was significantly
higher for ICD patients both at the index hospitalization
and during follow up. Both differences were driven
mainly by the fixed difference between the two predom-
inant DRG tariffs in the two groups. These estimates
provide an insight into the economic impact of ICDs. In
fact, given that cost assessment represents essential part
for defining value of DRG tariff, the latter is frequently
used as the “proxy” of hospital costs of specific patient
group. However, it has been argued that costing is not
the only ingredient in determining DRG tariffs and that
DRG tariffs may not fully reflect the actual resource con-
sumption associated with patient’s management [23]. To
estimate actual cost per patient, we would need further
data on the resources used and their unit costs, which
were not available in the present study.
The finding of similar LOSs and costs during follow-
up in patients who did and did not receive an ICD is of
interest, because in ICD patients prevention of sudden
cardiac death by termination of ventricular tachyarrhyth-
mia has been found to be associated with a subsequent
increased risk of heart failure, with a potential risk of in-
creased hospitalization for heart failure [24]. In RCTs,
the proportion of non-sudden deaths (including heart
failure) showed a relative increase in patients given a
prophylactic ICD compared with controls, though the
absolute number of heart failure deaths was not in-
creased [25].
A criticism of our study is related to the interpretation
of the results in terms of the causal relationship between
ICDs and mortality. Clinicians treat patients with ICDs
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be correlated with pre-treatment mortality. Thus, be-
cause we do not know everything about clinicians’ deci-
sions, our treatment and control groups might differ in
some unobservable characteristic. This possibility cannot
be excluded and is an important issue when interpreting
the evidence. However, two features of our study must be
highlighted in this regard.
First, though selection based on unobservables is an in-
trinsic problem of non-experimental evidence, the rele-
vance of our results does not depend on the correct
identification of a causality relationship (which can be
achieved only through proper clinical trial designs). From
a health policy perspective, our results should be
interpreted as important evidence that the real world use
of a new medical technology, the ICD, is in line with the
clinical evidence and that the health system is not signifi-
cantly distorting the application of this effective but
expensive preventive technique. It is noteworthy that
a systematic review and meta-analysis published by
Ezekowitz et al. found that mortality over time was simi-
lar between ICD patients enrolled in RCTs and those in
observational studies (both prospective and retrospec-
tive) [7].
Second, if the external validity of an RCT must be veri-
fied, observational data represent the best description of
the physicians’ behavior and patients’ outcomes. A cer-
tain degree of bias, excluded by the design of RCTs, is
thus unavoidable in this context. Alternatively, some
might prefer to use a more structured approach in which
the treatment is assumed to be assigned according to
pre-specified criteria, generally coming from a theoretical
model (e.g. see Heckman [27]). However, these method-
ologies were primarily developed for cases in which the
analyst has substantial information about each individual
(e.g. obtained from a survey) and can use extra matching
variables to predict selection for treatment. Here, we
know only what we could observe from administrative
datasets and used all the available information for
matching. Hence, we see no further advantage in intro-
ducing heavy discretionary assumptions about the selec-
tion process in this context.
Conclusions
Although we acknowledge its limitations, we believe that
the present paper contributes to the existing literature by
illustrating the potential use of administrative datasets in
evaluating the benefits of the implementation of new
technologies in the real world. There is huge potential in
using these data that is often underestimated in the sci-
entific literature. In the specific case of ICDs in the real
world setting of a region of Italy, ICD therapy was associ-
ated with a positive impact on mortality in comparison
with patients matched for age and administrative andclinical variables. The survival benefit was associated
with greater expenditures for the index hospitalization,
but costs were similar during follow-up.
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